The University of Alabama has received approval from the Food and Drug Administration (FDA) to begin cultivating, administering and studying the impact of low-THC (tetrahydrocannabinol), high-CBD (cannabidiol) cannabis extracts on childhood and adult seizure disorders.
In April, Alabama Governor Robert Bentley signed into law Senate Bill 174 which authorizes the University of Alabama’s Department of Neurology to prescribe, produce and distribute low-THC cannabis extracts – such as cannabis oil and tinctures – to those with seizure disorders. The oil must be primarily CBD, and can contain no more than 3% THC.
The bill, named Carly’s Law in honor of 3-year-old Carly Chandler who suffers from epilepsy, will be funded with $1 million from the state’s Education Trust Fund. The university still needs to receive approval from the Drug Enforcement Administration before they can proceed, though receiving approval from the FDA is seen as the biggest hurdle.